The US conglomerate 3M has found three buyers for its pharmaceuticals business, from which it will earn $2.1 billion. In the USA, medicinal products will be sold to American GRACEWAY PHARMACEUTICALS for the sum of $875 million. European activity will go to the Swedish laboratory, MEDA, for the sum of $857 million, and the Asia-Pacific affiliates will be sold to the Australian investment funds, IRONBRIDGE CAPITAL and ARCHER CAPITAL, for the sum of 349 million. Activities sold account in total...